Commentary| Volume 90, ISSUE 6, P356-358, September 15, 2021

mGlu3 Metabotropic Glutamate Receptors—New Hope for Pharmacotherapy of Schizophrenia

  • Mariacristina Mazzitelli
    Department of Pharmacology and Neuroscience, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas
    Search for articles by this author
  • Volker Neugebauer
    Address correspondence to Volker Neugebauer, M.D., Ph.D.
    Department of Pharmacology and Neuroscience, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas

    Center of Excellence for Translational Neuroscience and Therapeutics, Texas Tech University Health Sciences Center, Lubbock, Texas

    Garrison Institute on Aging, Texas Tech University Health Sciences Center, Lubbock, Texas
    Search for articles by this author
      Long considered promising targets for several neurological and psychiatric conditions, metabotropic glutamate (mGlu) receptors present as many challenges as opportunities for novel and effective therapeutic strategies. Eight subtypes of these G protein–coupled receptors have so far been identified and are classified into three groups according to their sequence homology, pharmacological properties, and downstream signaling pathways. Group I (mGlu1 and mGlu5) couple to Gq proteins and largely have activating or facilitatory properties. Group II (mGlu2 and mGlu3) and group III (mGlu4, mGlu6, mGlu7, and mGlu8) couple to Gi/o proteins and generally have inhibitory signaling effects resulting in a decrease of neurotransmitter release.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Maksymetz J.
        • Moran S.P.
        • Conn P.J.
        Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.
        Mol Brain. 2017; 10: 15
        • Saini S.M.
        • Mancuso S.G.
        • Mostaid M.S.
        • Liu C.
        • Pantelis C.
        • Everall I.P.
        • et al.
        Meta-analysis supports GWAS-implicated link between GRM3 and schizophrenia risk.
        Transl Psychiatry. 2017; 7e1196
        • Tamaru Y.
        • Nomura S.
        • Mizuno N.
        • Shigemoto R.
        Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: Differential location relative to pre- and postsynaptic sites.
        Neuroscience. 2001; 106: 481-503
        • Stansley B.J.
        • Conn P.J.
        Neuropharmacological insight from allosteric modulation of mGlu receptors.
        Trends Pharmacol Sci. 2019; 40: 240-252
        • Dogra S.
        • Stansley B.J.
        • Xiang Z.
        • Qian W.
        • Gogliotti R.G.
        • Nicoletti F.
        • et al.
        Activating mGlu3 metabotropic glutamate receptors rescues schizophrenia-like cognitive deficits through metaplastic adaptations within the hippocampus.
        Biol Psychiatry. 2021; 90: 385-398
        • Di Menna L.
        • Joffe M.E.
        • Iacovelli L.
        • Orlando R.
        • Lindsley C.W.
        • Mairesse J.
        • et al.
        Functional partnership between mGlu3 and mGlu5 metabotropic glutamate receptors in the central nervous system.
        Neuropharmacology. 2018; 128: 301-313
        • Xu J.
        • Antion M.D.
        • Nomura T.
        • Kraniotis S.
        • Zhu Y.
        • Contractor A.
        Hippocampal metaplasticity is required for the formation of temporal associative memories.
        J Neurosci. 2014; 34: 16762-16773
        • Matrisciano F.
        • Panaccione I.
        • Grayson D.R.
        • Nicoletti F.
        • Guidotti A.
        Metabotropic glutamate 2/3 receptors and epigenetic modifications in psychotic disorders: A review.
        Curr Neuropharmacol. 2016; 14: 41-47
        • Litman R.E.
        • Smith M.A.
        • Doherty J.J.
        • Cross A.
        • Raines S.
        • Gertsik L.
        • et al.
        AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study.
        Schizophr Res. 2016; 172: 152-157
        • Nomura T.
        • Oyamada Y.
        • Fernandes H.B.
        • Remmers C.L.
        • Xu J.
        • Meltzer H.Y.
        • et al.
        Subchronic phencyclidine treatment in adult mice increases GABAergic transmission and LTP threshold in the hippocampus.
        Neuropharmacology. 2016; 100: 90-97

      Linked Article